Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | PTPRC | P08575 | 1/20 | 0.44 |
| ▸ | S100A4 | P26447 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29368452 | 1.00 | CYP1A2 (0.47) | CYP1A2ALDH1A1TDP1CYP3A4TSHR | |
| SCHEMBL28218218 | 0.90 | POLB (0.52) | CYP1A2ALDH1A1TDP1CYP3A4TSHR | |
| SCHEMBL19336225 | 0.90 | POLB (0.52) | CYP1A2ALDH1A1TDP1CYP3A4TSHR | |
| SCHEMBL5598378 | 0.89 | GSK3B (0.43) | CYP1A2ALDH1A1TDP1CYP3A4TSHR | |
| SCHEMBL38665418 | 0.89 | CYP1A2 (0.46) | CYP1A2ALDH1A1TDP1CYP3A4TSHR | |
| SCHEMBL18331626 | 0.89 | CYP1A2 (0.42) | CYP1A2ALDH1A1TDP1CYP3A4TSHR | |
| SCHEMBL13006522 | 0.89 | CYP1A2 (0.42) | CYP1A2ALDH1A1TDP1CYP3A4TSHR | |
| SCHEMBL29706685 | 0.86 | PTPRC (0.52) | CYP1A2ALDH1A1TDP1CYP3A4TSHR | |
| SCHEMBL9800931 | 0.86 | CYP1A2 (0.41) | CYP1A2ALDH1A1TDP1CYP3A4TSHR | |
| SCHEMBL2180238 | 0.85 | CA12 (0.44) | CYP1A2ALDH1A1TDP1CYP3A4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 241 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3060915-A2 | DETECTION OF CLEAVAGE ACTIVITY OF AN ENZYME | Mologic Limited (GB) | 2016-08-31 | — | — | EP | claimed |
| WO-2015059487-A2 | DETECTION OF CLEAVAGE ACTIVITY OF AN ENZYME | MOLOGIC LIMITED (GB) | 2015-04-30 | — | — | WO | claimed |
| US-20250213735-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2025-07-03 | — | — | US | disclosed |
| US-12320804-B2 | Detection of cleavage activity of an enzyme | MOLOGIC LIMITED (GB) | 2025-06-03 | — | — | US | disclosed |
| US-20250157661-A1 | MONITORING INFLAMMATION STATUS | MOLOGIC LIMITED (GB) | 2025-05-15 | — | — | US | disclosed |
| EP-3628045-B1 | COMPOUNDS | UNIV SHEFFIELD (GB) | 2024-07-03 | — | — | EP | disclosed |
| EP-3628045-B1 | COMPOUNDS | UNIV SHEFFIELD (GB) | 2024-07-03 | — | — | EP | disclosed |
| US-11953506-B2 | Monitoring inflammation status | MOLOGIC LIMITED (GB) | 2024-04-09 | — | — | US | disclosed |
| EP-3928100-B1 | TREATMENT STRATIFICATION FOR AN EXACERBATION OF INFLAMMATION | MOLOGIC LTD (GB) | 2023-03-22 | — | — | EP | disclosed |
| US-20230036854-A1 | HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS | THE UNIVERSITY OF SHEFFIELD (GB) | 2023-02-02 | — | — | US | disclosed |
| US-11427542-B2 | Compounds for treatment of cardiac arrhythmias and heart failure | ELEX BIOTECH, INC. (US) | 2022-08-30 | — | — | US | disclosed |
| WO-1996038471-A1 | DIPEPTIDES WHICH PROMOTE RELEASE OF GROWTH HORMONE | PFIZER INC. (US) | 1996-12-05 | — | — | WO | disclosed |
| WO-1996035713-A1 | DIPEPTIDES WHICH PROMOTE RELEASE OF GROWTH HORMONE | PFIZER, INC. (US) | 1996-11-14 | — | — | WO | disclosed |
| US-5026856-A | Bactericides | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1991-06-25 | — | — | US | disclosed |
| EP-0343560-A2 | Isoindoline derivative | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1989-11-29 | — | — | EP | disclosed |
| US-4414220-A | HUPOGLYCEMIC, ANTIDIABETIC | PFIZER INC. (US) | 1983-11-08 | — | — | US | disclosed |
| US-4333932-A | DIHYDROISOINDOLES, HYPOGLYCEMIC, ANTIDIABETIC | PFIZER INC. (US) | 1982-06-08 | — | — | US | disclosed |
| EP-0010896-B1 | ORGANIC DIAMINE COMPOUNDS FOR USE AS ORAL HYPOGLYCEMIC AGENTS AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER INC. (US) | 1981-12-30 | — | — | EP | disclosed |
| US-4220650-A | HYPOGLYCEMIC | PFIZER INC. (US) | 1980-09-02 | — | — | US | disclosed |
| EP-0010896-A1 | Organic diamine compounds for use as oral hypoglycemic agents and pharmaceutical compositions thereof | PFIZER INC. (US) | 1980-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250213735-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | NPY1R, NPY2R, NPY4R | CYP1A2 4022/4885ALDH1A1 3906/4885TDP1 1600/4885 |
| US-20230036854-A1 | HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS | MC2R, AGTR2, NR3C2 | CYP1A2 396/4885ALDH1A1 2923/4885TDP1 4742/4885 |
| US-11427542-B2 | Compounds for treatment of cardiac arrhythmias and heart failure | RYR2, RYR1, CACNA1F | CYP1A2 1378/4885ALDH1A1 2527/4885TDP1 1569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.